Figure 2. Enrollment of patients administered kisspeptin-54 to induce egg maturation during IVF therapy.

The first two patients were randomized to receive kisspeptin-54 at the dose of 1.6 nmol/kg during IVF therapy. Clinically difficult egg collection was reported 36 hours following kisspeptin-54 injection in both patients. The subsequent nine patients were therefore randomized 1:1:1 to 3.2, 6.4, or 12.8 nmol/kg. Clinically difficult egg collection was reported 36 hours following kisspeptin-54 injection in all patients in the 3.2 nmol/kg cohort. Subsequent patients were therefore randomized 1:1 to 6.4 or 12.8 nmol/kg kisspeptin-54 (n = 24 per group). No patients were lost to follow-up, and no patients discontinued the intervention. The outcome data for all patients who were randomized were included in the final data analysis.